HOME >> BIOLOGY >> NEWS
Potential new anthrax therapy discovered

Findings could lead to novel treatments against other bacterial infections

Boston, MAA study by Harvard Medical School researchers in the April 27 Science suggests a mutation in the anthrax toxin, which prevents poisoning, may lead to a double-pronged pharmaceutical that is equally effective as a vaccine and as a faster-acting and more broadly protective therapy than currently available.

Death from anthrax is due to the toxin produced by the bacteria. In its airborne form, just a teaspoonful of anthrax could wipe out hundreds of people. Though rarely a natural threat to humans, anthrax is especially dangerous as a potential weapon in terrorism and biological warfare.

Though a vaccine exists, most people have no vaccine-induced immunity to anthrax because the rarity of infection makes a mass vaccination program impractical. Yet current therapies demand that any unvaccinated person exposed to the bug receive antibiotic therapy before symptoms occur. Otherwise, the victim with systemic anthrax dies rapidly. The discovery by R. John Collier and colleagues may offer a better way to fight back before or after infection.

The researchers tested whether they could prevent infection using forms of the anthrax bacterium with a mutation in a toxin subunit dubbed "protective antigen." When protective-antigen mutants were injected together with a normally lethal mix of toxin, rats did not develop any symptoms of poisoning. The protective-antigen variants "totally protected the animals, whereas the control animals became moribund within 90 minutes," says Collier, the Maude and Lillian Presley Professor of Microbiology and Molecular Genetics at the Medical School. "Were most encouraged about the experiments in rats. The results are remarkable."

The protective-antigen mutants are good candidates for an anthrax therapy because the normal form of protective antigen in and of itself is already known to be safe in humans: it is the major component
'"/>

Contact: John Lacey
john_lacey@hms.harvard.edu
617-432-0441
Harvard Medical School
26-Apr-2001


Page: 1 2 3

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential blood test for colon cancer risk
3. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
4. Potential cause of arthritis discovered
5. Potential of regenerative medicine explored
6. Potential therapy reported for children, adults with end-stage liver disease
7. Potential allergy vaccine boosts hope for sufferers
8. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Potential new anthrax therapy discovered

(Date:5/17/2013)... An international team of scientists using a new X-ray ... a living frog embryo in greater detail than ever ... biological research and the search for new treatments for ... Institut fr Technologie in Germany, in collaboration with the ... Argonne National Laboratory, released the most precise depiction ever ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... shown a gene involved in neurodegenerative disease also plays ... circadian clock. , In a study of the ... Ataxin-2, keeps the clock responsible for sleeping and waking ... of the fruit fly,s sleep-wake cycle is disturbed, making ... fly. , The discovery is particularly interesting because ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
(Date:5/17/2013)... JOSE, Calif. , May 17, 2013 /PRNewswire-iReach/ ... agreement has been reached with Switzerland ... portfolio of anti-infective human monoclonal antibody (mAb) products, ... anti-infective human mAb products for treatment of infections ... of Staphylococcus aureus , Pseudomonas aeruginosa ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
(Date:5/16/2013)... 16, 2013 The Stirling Ultracold ... Cooling, Inc., Athens, OH, USA, won the Outstanding New ... International Society for Biological and Environmental Repositories (ISBER) at ... to one product annually, recognizes the company’s development and ... freezer. The award was presented to Global Cooling’s ...
(Date:5/16/2013)... May 16, 2013 A new ... models, from Cole-Parmer is designed to meet the ... includes: , The new Cole-Parmer® MS-3400 Centrifuges ... in the lab. They ensure a powerful and ... specimen separation. Their standard four-place swinging buckets hold ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2
Cached News: